The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

The Singapore-based AI clinical trial engine powering Asia’s—especially China’s—rapid rise in the biotech industry. Deep ...

Nina Moreno, Nelson Labs, explains how rapid sterility testing is reshaping pharmaceutical quality control—cutting release ...

Enter generative AI, which the pharma industry is adopting at a terrific rate. By ingesting and analysing vast biological ...

Rare diseases, defined by FDA as “a disease or condition that affects less than 200,000 people in the United States” (1), may ...

Impella, which J&J touts as the world’s smallest heart pump, has a range of devices used for various heart conditions. Lexeo ...

Octapharma has received approval from the US FDA for a new 2-g formulation of Fibryga for use in patients with AFD.

Key stocks like IRB Infra, Gland Pharma, and NCL Industries show strong performance and new orders, attracting investor ...

Equity-Insider.com News Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to $138 billion as major players scramble to secure proven cancer ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Eir Partners Capital, LP ("Eir" or the "Firm"), a private equity firm focused on health tech and tech-enabled services, today announced the final close of Eir Partners III ("Fund III"). Fund III ...

The partnership aims to achieve €8.6m in retail sales value in three years and was developed by an Irish team of 17 at TCD ...